WaveMan
WaveMan · Company
SRTS · Sensus Healthcare, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

SRTS Sensus Healthcare (SRTS) Insider Trading, Ownership & Congress Trades

Medical Devices · Surgical & medical instruments & apparatus · CIK 0001494891
Quote by TradingView
C-suite buying · 1
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
11
13F, latest reported quarter

What the filings say about SRTS

Insiders, 180 days
+$568.5K net bought
2 buyers

Sensus Healthcare insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Sensus Healthcare, Inc. insiders bought a net $568.5K of stock across 66 Form 4 purchases and sales, with 2 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Sachetta Eric
Director
BUY
2026-08-31 SEC
27,304
$96.6K
-15.3%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 buys), the last on Aug 28, 2026.
  • -5.5% median (-5.2% mean) 90-day return after 4 previous buys.
  • The trade is 9.3% of the 294,784 shares held after it.
  • 1 other insider bought within 30 days.
  • 11 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sachetta Eric bought about $96.6K of SRTS on Aug 31, 2026; 1 other insider bought within 30 days and 11 funds added in the latest 13F quarter.
Sachetta Eric
Director
BUY
2026-08-31 SECtraded 2026-08-28
37,537
$129.0K
-15.3%
Context
  • 9 earlier Form 4 trades (code P or S) here by this insider (9 buys), the last on Aug 27, 2026.
  • -5.5% median (-5.2% mean) 90-day return after 4 previous buys.
  • The trade is 14.0% of the 267,480 shares held after it.
  • 1 other insider bought within 30 days.
  • 11 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sachetta Eric bought about $129.0K of SRTS on Aug 28, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 11 funds added in the latest 13F quarter.
Sachetta Eric
Director
BUY
2026-08-28 SECtraded 2026-08-27
10,925
$34.8K
-20.3%
Context
  • 8 earlier Form 4 trades (code P or S) here by this insider (8 buys), the last on Aug 26, 2026.
  • -5.5% median (-5.2% mean) 90-day return after 4 previous buys.
  • The trade is 4.8% of the 229,943 shares held after it.
  • 1 other insider bought within 30 days.
  • 11 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sachetta Eric bought about $34.8K of SRTS on Aug 27, 2026; 1 other insider bought within 30 days and 11 funds added in the latest 13F quarter.
Sachetta Eric
Director
BUY
2026-08-28 SECtraded 2026-08-26
9,708
$31.9K
-20.3%
Context
  • 7 earlier Form 4 trades (code P or S) here by this insider (7 buys), the last on Aug 24, 2026.
  • -5.5% median (-5.2% mean) 90-day return after 4 previous buys.
  • The trade is 4.4% of the 219,018 shares held after it.
  • 1 other insider bought within 30 days.
  • 11 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sachetta Eric bought about $31.9K of SRTS on Aug 26, 2026; 1 other insider bought within 30 days and 11 funds added in the latest 13F quarter.
Sachetta Eric
Director
BUY
2026-08-25 SECtraded 2026-08-24
34,697
$112.9K
-14.3%
Context
  • 6 earlier Form 4 trades (code P or S) here by this insider (6 buys), the last on Aug 21, 2026.
  • -5.5% median (-5.2% mean) 90-day return after 4 previous buys.
  • The trade is 16.6% of the 209,310 shares held after it.
  • 1 other insider bought within 30 days.
  • 11 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Sachetta Eric bought about $112.9K of SRTS on Aug 24, 2026, the largest insider purchase at the company on our record; 1 other insider bought within 30 days and 11 funds added in the latest 13F quarter.
66 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 61 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$568.5K over 180 days
+$563.5K over 90 days
more than 88% of Medical Devices
Congress
no House purchase disclosed in the last 12 months
Funds
11 funds bought in last quarter
below 83% of Medical Devices
Revenue
-34.3% year over year
below 93% of Medical Devices
Margin
-28.1% net margin
below 58% of Medical Devices
Buybacks
$300.0K repurchased, FY to 2025-12-31
below 92% of Medical Devices
Short interest
1.7% of the float short (float per yahoo 2026-10-26) · 7.8 days to cover · settled 2026-09-30
below 70% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days

Watch SRTS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-14.3%12M
-18%+8%+35%+61%2025-102025-122026-022026-042026-062026-082026-10 2026-08-28 · Sachetta Eric bought $129.0K2026-08-24 · Sachetta Eric bought $112.9K2025-11-18 · Sardano Joseph C bought $100.8K2026-08-31 · Sachetta Eric bought $96.6K2026-08-20 · Sachetta Eric bought $75.1K2026-08-20 · Sardano Joseph C bought $60.5K2026-08-27 · Sachetta Eric bought $34.8K2026-08-26 · Sachetta Eric bought $31.9K2025-11-21 · Sachetta Eric bought $27.5K2026-08-21 · Sachetta Eric bought $22.8K2025-11-13 · Sachetta Eric bought $11.2K2026-02-24 · Sachetta Eric bought $7.6K2026-05-12 · Sachetta Eric bought $5.0K2025-11-11 · Sardano Michael bought $4.3K2025-11-11 · Sardano Michael bought $4.3K2025-11-18 · Sardano Michael bought $3.8K2025-11-11 · Sardano Michael bought $3.3K2025-11-11 · Sardano Michael bought $3.3K2025-11-11 · Sardano Michael bought $1.0K2025-11-11 · Sardano Michael bought $992
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns SRTS: institutional holders (13F)

13F holdings, latest reported quarter
Pacific Ridge Capital Partners, LLC
789,675 sh
$2.4M
VANGUARD CAPITAL MANAGEMENT LLC
660,402 sh
$2.0M
DIMENSIONAL FUND ADVISORS LP
316,121 sh
$954.8K
Divisadero Street Capital Management, LP
278,485 sh
$841.0K
RENAISSANCE TECHNOLOGIES LLC
242,334 sh
$731.8K

Congress trades in SRTS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

SRTS planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

SRTS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
M3Sixty Income and Opportunity Fund
$441.9K position · as of 2026-05-31
2.6%
North Star Micro Cap Fund
$388.1K position · as of 2026-05-31
0.2%
Adara Smaller Companies Fund
$960.8K position · as of 2026-05-31
0.1%
iShares Micro-Cap ETF
$140.0K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$9.2K position · as of 2026-06-30
0.0%
Avantis U.S. Small Cap Equity Fund
$3.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Executive pay vs shareholder return · Mr. J Sardano
CEO pay, headline and as actually paid, against the company's return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2024
$1.3M
$1.3M
$963.8K
-4%
n/a
2023
$687.6K
$687.6K
$404.8K
-68%
n/a
2022
$754.4K
$754.4K
$421.9K
+3%
n/a
Tagged by the company under SEC Item 402(v). Returns are cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $568.5K bought by insiders over 180 days, 11 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
PENBLFSMTDSIBNWRBYISRGTXGDXCMEWTMDXOMIRMD

SRTS financials

Revenue growth
-34.3%
XBRL, annual
Net margin
-28.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$17.5M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-88.5%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$7.0M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-34.8%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-30.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on capital employed
-29.7%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-15.0%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$27.5M$41.8M$24.4M$44.5M
Gross profit$11.9M$24.4M$14.1M$29.6M
Operating income-$10.3M$8.1M-$382.0K$14.8M
Net income-$7.7M$6.6M$485.0K$24.2M
EPS (diluted)-0.470.410.031.46
Operating cash flow$528.0K-$831.0K-$2.1M-$1.4M
Cash$22.1M$22.1M$23.1M$25.5M
Buybacks$300.0Kn/a$27.0K$3.0M
SEC XBRL, fiscal years, as known on 2026-10-28

SRTS Stock Sonar score 5/7 axes

Find similar shapesCompare

SRTS ranks highest on insider conviction (81st percentile) and risk and compliance (80th), and lowest on growth (7th), among Medical Devices peers.

ProfitGrowthInsidersInstitutionsRisk
Profitability
41
Inputs
  • Return on equity-34.8% · 45 pct, sector of 183
  • Return on assets-30.9% · 38 pct, sector of 214
  • Return on invested capitalpre-tax loss, no effective tax rate to apply
  • Return on capital employed-29.7% · 40 pct, sector of 188
Growth
7
Inputs
  • Revenue growth, YoY-34.3% · 7 pct, sector of 219
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
81
Inputs
  • Net Form 4 buying (codes P and S), 180d$569K · 88 pct, sector of 140
  • Insider buyers, 180d2 · 74 pct, sector of 142
Institutional and government
18
Inputs
  • Funds adding, latest quarter11 · 17 pct, sector of 191
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$85K · 18 pct, sector of 50
Risk and compliance
80
Inputs
  • Short interest, % of float+1.7% · 75 pct, sector of 240
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+4.4% · 85 pct, sector of 198
2 not measured: Financial health, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

SRTS filings, in plain words

Are Sensus Healthcare insiders buying or selling SRTS?

In the 180 days to 2026-10-28, Sensus Healthcare insiders were net buyers, a net $568.5K across purchases and sales reported on Form 4, by 2 buyers.

Read the full summary

In the 180 days to 2026-10-28, Sensus Healthcare insiders were net buyers of SRTS, a net $568.5K across purchases and sales reported on Form 4 by 2 buyers. 2 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies